Sierra Oncology, Inc. Stock: price and insider trades · United States

In terms of history, Sierra Oncology developed as a research-driven biotech with activities concentrated in the United States and, through regulatory filing pathways, Europe. The company’s 2022 regulatory work around momelotinib became the key catalyst that attracted strategic interest from larger pharmaceutical players. GSK announced an agreement to acquire Sierra Oncology for about $1.9 billion, and later confirmed completion of the acquisition. That deal effectively monetized the company’s main clinical asset and ended Sierra Oncology’s life as an independent public issuer. ([gsk.com](https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-sierra-oncology-for-19bn/?utm_source=openai))

For investors in France, Belgium, and Switzerland, the case is important mainly as a historical U.S. biotech compendium rather than a current operating equity story. The company was listed on NASDAQ in the United States, and its market relevance came from one principal program, momelotinib, plus the strategic optionality embedded in the anemia segment of myelofibrosis care. Sierra Oncology did not have the diversified product mix of a commercial pharma group; instead, it was a pipeline-centric specialist whose competitive standing depended on clinical differentiation, regulatory milestones, and partner or acquirer interest. Following the GSK acquisition, subsequent market relevance is primarily confined to legacy SEC records, including insider-transaction filings such as Form 4, rather than ongoing public-market operations. ([gsk.com](https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-sierra-oncology-for-19bn/?utm_source=openai))